Wire · opportunities
Projecting Big Growth For This $13 Billion Biotech Name
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 October 2026 · Fusion42 review
BridgeBio Pharma, a $13 billion biotech company, showed strong sales growth for its ATTR-CM treatment Attruby and is pursuing FDA approvals for three additional drugs targeting rare diseases with large market potential. The company aims to become cash flow positive by late 2027, with revenues expected to surpass $4.5 billion by 2030.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can capitalise on BridgeBio’s expanding rare disease portfolio and upcoming FDA approvals by positioning around their growth trajectory now. This is a moment to gain exposure to a company moving from a single-product base to multiple high-value therapies.
◆ Coverage
1 source · 11 Oct 2026
◆ Related on Wire
◆ Topics